Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

User asks if stacking Alfatradiol and Fluridil is effective for hair loss. Alfatradiol is a weaker, topical 5ar inhibitor, while Fluridil is an anti-androgen preventing DHT binding to hair follicles.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

A user is seeking advice on purchasing RU58841 with Minoxidil in Canada and is concerned about the vehicle used for the solution. They also inquire about the differences between RU58841 and topical finasteride in terms of efficacy.

A 19-year-old is experiencing diffuse thinning and has been on finasteride for 6 months, noticing a slower but still concerning rate of hair loss. They started taking 0.5mg of dutasteride once a week in addition to 1.25mg of finasteride on other days and are seeking advice on this treatment approach.

A user experienced hair loss due to a folic acid deficiency and saw hair regrowth after taking a folic acid supplement. They advise checking for a folic acid deficiency before spending money on other treatments.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.

The user has been treating hair loss for 7 months using a combination of pyrilutamide, a topical mix of finasteride and minoxidil, microneedling, a topical mix of GHK-Cu and minoxidil, ketoconazole shampoo, fish collagen peptides, zinc, and vitamin D3. Another user suggests that continuous small improvements could lead to significant hair regrowth over time.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.

The user switched from finasteride and topical minoxidil to oral dutasteride and minoxidil, with plans to add RU58841, to improve hair growth and address a stubborn bald spot. Despite initial shedding, the user noticed thicker, darker hair and plans to continue the treatment or consider a hair transplant.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

The user experienced hair loss and started using minoxidil (5%) and finasteride (0.5 mg daily) with inconsistent application but still saw noticeable improvements by the end of January. They use the liquid form of minoxidil.

Imidazole drugs like ketoconazole inhibit certain enzymes and prevent DHT from binding to SHBG, increasing free DHT in the bloodstream, which may contribute to balding. The discussion questions how these drugs help with hair loss despite this effect.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The user has been using finasteride for 8 months, minoxidil for 4 months, and a 1.5mm roller weekly, along with vitamins, fish oil, and nizoral. They report noticeable hair improvement with no side effects, attributing significant progress to minoxidil.

User shared 7-month hair loss progress pictures. They used Minoxidil 10% topical solution.

The conversation is about someone's progress with hair regrowth using finasteride and minoxidil from December 1st to May 10th. They also mention using a topical treatment with a concentration of 0.004 per spray.

Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.

The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.